Literature DB >> 6426551

A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID).

S Kinoshita, J Harrison, J Lazerson, C F Abildgaard.   

Abstract

A new type II variant form of von Willebrand's disease has been recognized in a mother and daughter who have bleeding manifestations typical of von Willebrand's disease. Laboratory findings include consistently prolonged bleeding times, with normal levels of factor VIII procoagulant and antigen, but decreased ristocetin cofactor activity. Electrophoresis in SDS 1.5% agarose gel and reaction with 125I-labeled anti-factor VIII-related antigen rabbit IgG, followed by autoradiography, revealed that both plasma and platelets lack the large multimers of factor VIII-related antigen. In 2.5% gel, the propositus plasma lacked the normal "triplet" pattern. In 3.0% gel, a 5-band pattern was observed in normal, type IIA, and type IIB plasma, whereas type IIC plasma revealed a 2-band pattern. The patient's plasma revealed a 4-band pattern distinctly different from normal or other type II variants. We suggest that this new variant be labeled type IID, until a more appropriate nomenclature is developed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426551

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Cloning and characterization of two cDNAs coding for human von Willebrand factor.

Authors:  J E Sadler; B B Shelton-Inloes; J M Sorace; J M Harlan; K Titani; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

3.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

5.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.

Authors:  M Furlan; R Robles; D Affolter; D Meyer; P Baillod; B Lämmle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  Investigation of a kindred with a new autosomal dominantly inherited variant type von Willebrand's disease (possible type IID).

Authors:  F G Hill; M S Enayat; A J George
Journal:  J Clin Pathol       Date:  1985-06       Impact factor: 3.411

8.  Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).

Authors:  T S Zimmerman; J A Dent; Z M Ruggeri; L H Nannini
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

9.  An explanation for minor multimer species in endothelial cell-synthesized von Willebrand factor.

Authors:  D C Lynch; T S Zimmerman; E H Ling; P J Browning
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

10.  Comparison of two dimensional immunoelectrophoresis and multimer analysis in the study of von Willebrand factor.

Authors:  M A Howard; A Oates; B G Firkin
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.